UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000030778
Receipt number R000035145
Scientific Title The analysis of the microbiota as biomarkers of response to anticancer drugs in metastatic solid cancers
Date of disclosure of the study information 2018/01/12
Last modified on 2018/01/12 01:50:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The analysis of the microbiota as biomarkers of response to anticancer drugs in metastatic solid cancers

Acronym

The analysis of Microbiota in the efficacy of anticancer drugs

Scientific Title

The analysis of the microbiota as biomarkers of response to anticancer drugs in metastatic solid cancers

Scientific Title:Acronym

The analysis of Microbiota in the efficacy of anticancer drugs

Region

Japan


Condition

Condition

Advanced or recurrent cancer

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To analyze the effect of the microbiota in anticancer drugs efficacy and toxicity

Basic objectives2

Others

Basic objectives -Others

The effect of intratumor bacteria on anticancer drugs efficacy and toxicity

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To identify oral and gut microbiota signatures for responders and nonresponders to anticancer drugs.

Key secondary outcomes

Progression-free survival. Overall survival
Oral and gut microbiota signatures for patients with early tumor shrinkage
Oral and gut microbiota signatures for adverse event
To identify species of intratumor bacteria
12-month PFS rate in cancer patients with or without intratumor bacteria
Relationship intratumor bacteria and cancer tissue expression of immune-related proteins
Detection of bacterial 16S rRNA in human blood
Plasma levels of cytokines or chemokines associated with microbiota signatures
Immune cell subsets in peripheral blood analysis by flow cytometry


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Age of more than 20 years old.
(2) Written informed consent.

Key exclusion criteria

(1)Serological positive for HBs antigen, HCV antibody, or HIV antibody
(2) An inappropriate case judged by doctor in charge.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazuyuki Hamada

Organization

Showa University

Division name

Department of Internal Medicine, Division of Medical Oncology

Zip code


Address

1-5-8, Hatanodai, Shinagawa-ku, Tokyo 142-8666, JAPAN

TEL

03-3784-8402

Email

hamadakaz@med.showa-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kazuyuki Hamada

Organization

Showa University

Division name

Department of Internal Medicine, Division of Medical Oncology

Zip code


Address

1-5-8, Hatanodai, Shinagawa-ku, Tokyo 142-8666, JAPAN

TEL

03-3784-8402

Homepage URL


Email

amadakaz@med.showa-u.ac.jp


Sponsor or person

Institute

Department of Internal Medicine, Division of Medical Oncology, Showa University School of Medicine.

Institute

Department

Personal name



Funding Source

Organization

Department of Internal Medicine, Division of Medical Oncology, Showa University School of Medicine.

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Department of Clinical Immune Oncology, Clinial Research Institute of Clinical Pharmacology and Therapeutics, Showa University.

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

昭和大学病院(東京都)


Other administrative information

Date of disclosure of the study information

2018 Year 01 Month 12 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2017 Year 12 Month 26 Day

Date of IRB


Anticipated trial start date

2018 Year 01 Month 12 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

An observational study of solid cancer patients.
To identify oral and gut microbiota signatures for responders and nonresponders to anticancer drugs.
Progression-free survival. Overall survival
Oral and gut microbiota signatures for patients with early tumor shrinkage
Oral and gut microbiota signatures for adverse event
To identify species of intratumor bacteria
12-month PFS rate in cancer patients with or without intratumor bacteria
Relationship intratumor bacteria and cancer tissue expression of immune-related proteins
Detection of bacterial 16S rRNA in human blood
Plasma levels of cytokines or chemokines associated with microbiota signatures
Immune cell subsets in peripheral blood analysis by flow cytometry


Management information

Registered date

2018 Year 01 Month 12 Day

Last modified on

2018 Year 01 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035145


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name